RepliCel Retains Christina Cameron as Canadian Investor Relations Consultant

RepliCel Retains Christina Cameron as Canadian Investor Relations Consultant 
NEWS RELEASE TRANSMITTED BY Marketwired 
FOR: RepliCel Life Sciences Inc. 
TSX VENTURE SYMBOL:  RP
OTCQB SYMBOL:  REPCF 
JUNE 5, 2014 
RepliCel Retains Christina Cameron as Canadian Investor Relations Consultant 
VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 5, 2014) - RepliCel Life
Sciences Inc. (TSX VENTURE:RP)(OTCQB:REPCF), today announced that it has
retained Christina Cameron as its Canadian Investor Relations consultant to
create and execute the company's investor relations strategy within
Canada. 
Ms. Cameron is a life sciences capital markets expert with over 13 years of
experience in investor relations and investment banking. Her extensive network
of sell-side, buy-side, retail investors and industry partners will be
invaluable to RepliCel as it looks to broaden its Canadian stakeholder base. 
Prior to consulting, Ms. Cameron led the in-house investor relations program
for Medicago Inc., a TSX listed Canadian life science company, which was
recently acquired by Mitsubishi Tanabe Pharma Corporation, a big pharma
company. She has also spent 10 years in the life science capital markets
industry as a senior member of the TMX Group's investor relations arm and
as a healthcare banker at HSBC Securities and Vengate Capital. 
"Ms. Cameron's experience will be a significant asset to the company
as we continue to develop our strategic investor relations program,"
stated Gemma Fetterley, VP Finance of RepliCel. 
Pursuant to its Stock Option Plan, the Company granted 100,000 options to Ms.
Cameron. The options vest over a one year period and are exercisable at $0.65
per share until June 1, 2019. 
About RepliCel Life Sciences 
RepliCel is a regenerative medicine company developing autologous cell
therapies that treat functional cellular deficits including chronic tendon
injuries, pattern baldness and damaged and aging skin. Phase 2 trials are
planned for RCT-A-01, a treatment for chronic Achilles tendinosis and RCH-01, a
treatment for pattern baldness in 2014. A Phase 1 trial for RCS-01, a treatment
for damaged and aging skin is also targeted for 2014. All products are based on
RepliCel's innovative technology which utilizes cells isolated from a
patient's own healthy hair follicles which are then replicated using the
company's proprietary manufacturing and cell expansion platform. Shiseido
Company has acquired an exclusive geographic license for RCH-01 in certain
Asian countries including Japan, China and South Korea. 
On Behalf of the Board 
RepliCel Life Sciences Inc. 
David Hall, President and Chief Executive Officer 
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release. 
-30-
FOR FURTHER INFORMATION PLEASE CONTACT: 
RepliCel Life Sciences
Tammey George
Director of Communications
604-248-8696
tg@replicel.com
or
US Investor Relations:
Westwicke Partners, LLC
Robert H. Uhl, Managing Director
858-356-5932
robert.uhl@westwicke.com
or
Canadian Investor Relations:
Christina Cameron
christina@clcameron.com 
INDUSTRY:  Pharmaceuticals and Biotech - Biotech, Pharmaceuticals and Biotech -
Trials 
SUBJECT:  BFC 
-0-
-0- Jun/05/2014 21:14 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.